QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Northwest Biotherapeutics, Inc. (NWBO) And Partners Achieve “Significant Milestones” To Move DCVax® Toward Clinical Trial 0 comments
    Apr 24, 2012 5:37 PM | about stocks: NWBO

    Northwest Biotherapeutics, a biotech company focused on developing immunotherapy products to treat cancers more effectively than current treatments, today made a joint announcement with the Fraunhofer IZI Institute that 13-month collaborative efforts have resulted in the completion of "significant milestones" in NW Bio's DCVax®-L program for brain cancer in Germany.

    NW Bio said it is now positioned to soon advance with both its clinical trial program and hospital exemption cases under the compassionate use cases, per the German Drug Act.

    "It has been a very intensive process for well over a year to complete these important milestones in Germany," Linda Powers, CEO of NW Bio stated in the press release. "We are grateful to have such a strong and close working relationship with our partner, Fraunhofer IZI, and to benefit from their extensive expertise with German and European regulatory requirements. We are also excited to now be poised to move forward in the near term with our clinical trial program and Hospital Exemption cases in Germany, with its population of nearly 85 million people."

    NW Bio's contract manufacturer, Cognate BioServices, teamed with Fraunhofer IZI to carry out the four-month long technology transfer of the manufacturing process for DCVax®-L.

    The milestones include the completion and filing of all necessary documentation and applications as part of the regulatory process; and the parties are now awaiting the final inspection required before the manufacturing authorization can be granted and manufacturing can proceed for clinical trials and hospital exemption cases. The inspection is scheduled for June 2012.

    For more information visit nwbio.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: NWBO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.